Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
ROSELAND, N.J., May 03, 2017 -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the first three months ended March 31, 2017, on Friday, May 12, 2017. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com. The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 14929495.
In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Friday, May 12, 2017 at 11:30 AM ET through 11:30 PM ET on May 19, 2017, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 14929495.
About Emisphere
Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12. Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions. Our capabilities range from early proof of concept, to extensive development and commercial capabilities.
Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties. Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. For more information please visit www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8000 [email protected]
